Article ID Journal Published Year Pages File Type
2540359 International Immunopharmacology 2016 7 Pages PDF
Abstract

•TR6 significantly inhibited MPO activity, and LPS-induced production of TNF-α, IL-1β and IL-6.•TR6 significantly inhibited LPS-induced TNF-α and IL-6 production.•TR6 significantly inhibited LPS-induced NF-κB and MAPKs activation.

[TRIAP]-derived decoy peptides have anti-inflammatory properties. In this study, we synthesized a TRIAP-derived decoy peptide (TR6) containing, the N-terminal portion of the third helical region of the [TIRAP] TIR domain (sequence “N”-RQIKIWFQNRRMKWK and -KPGFLRDPWCKYQML-“C”). We evaluated the effects of TR6 on lipopolysaccharide-induced mastitis in mice. In vivo, the mastitis model was induced by LPS administration for 24 h, and TR6 treatment was initiated 1 h before or after induction of LPS. In vitro, primary mouse mammary epithelial cells and neutrophils were used to investigate the effects of TR6 on LPS-induced inflammatory responses. The results showed that TR6 significantly inhibited mammary gland hisopathologic changes, MPO activity, and LPS-induced production of TNF-α, IL-1β and IL-6. In vitro, TR6 significantly inhibited LPS-induced TNF-α and IL-6 production and phosphorylation of NF-κB and MAPKs. In conclusion, this study demonstrated that the anti-inflammatory effect of TR6 against LPS-induced mastitis may be due to its ability to inhibit TLR4-mediated NF-κB and MAPK signaling pathways. TR6 may be a promising therapeutic reagent for mastitis treatment.

Related Topics
Life Sciences Immunology and Microbiology Immunology
Authors
, , , , , , , , ,